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Abstract 
This article briefly discusses 10 topics that were selected by the author as top 10 discoveries published in 2019 
in the broader field of neuro-oncological pathology (so including neurosciences as well as clinical neuro-
oncology but with implications for neuro-oncological pathology). Some topics concern new information on 
immunohistochemical and molecular markers that enable improved diagnosis of particular tumors of the cen-
tral nervous system (CNS) and information on a refined classification of medulloblastomas. Subsequently, sev-
eral papers are discussed that further elucidate some pathobiological aspects of especially medulloblastomas 
(histogenesis, molecular evolution) and diffuse gliomas (mechanisms involved in CNS infiltration, role of cancer 
stem(-like) cells, longitudinal molecular evolution). The remaining topics concern progress made in vaccination 
therapy for glioblastomas and in using cerebrospinal fluid for liquid biopsy diagnosis of gliomas. Clearly, sub-
stantial, and sometimes even amazing progress has been made in increasing our understanding in several areas 
of neuro-oncological pathology. At the same time, almost every finding raises new questions, and translation of 
new insights in improving the outcome for patients suffering from CNS tumors remains a huge challenge. 
Keywords: Brain tumor, Neuropathology, Molecular diagnostics, Glioma, Medulloblastoma, Methylome analysis 
 
Introduction 
Looking back from time to time is good. The re-
quest of the editor-in-chief of this journal to contribute a 
review on ‘top 10 discoveries’ in neuro-oncology pub-
lished in 2019 was the reason for the author to look back 
in a somewhat more structured way in order to select 
which topics could/should qualify for such a label. From 
the start it was clear that there are multiple ways to 
shape such a selection process. To cut a long story short, 
keeping the readership of Free Neuropathology in mind 
and with some help of the editor-in-chief of this journal, 
the choice was made to select topics based on original 
papers published in 2019 from a broad range of journals, 
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important criteria being that indeed relevant progress 
was made and that in one way or another the findings 
can be expected to have substantial implications for 
neuro-oncological pathology. Furthermore, it was decid-
ed to not just focus on articles in the high(est)-impact 
journals and to aim for a somewhat broader blend of 
topics. 
Some topics presented in this review were selected 
based on just one article, while the information of two 
or three papers was combined for the discussion of oth-
er topics. The 10 topics that emerged from this (quite 
subjective!) selection process are: 
1. Lack of H3K27me3 staining is a promising surrogate 
marker for oligodendrogliomas [1] 
2. Improved molecular diagnosis of rare CNS tumor 
types [2, 3] 
3. Refined molecular classification of non-WNT/non-
SHH medulloblastomas [4] 
4. Histogenesis of posterior fossa tumors in children [5-
7] 
5. Longitudinal molecular analysis of diffuse gliomas [8] 
6. NOTCH1-SOX2 signaling controls glioma cell invasion 
in white matter tracts [9] 
7. ‘Synaptic cooption’ in glial and metastatic CNS tu-
mors [10-12] 
8. The role of cancer stem(-like) cells in glioblastomas 
[13] 
9. Personalized (neo)antigen vaccination therapy for 
glioblastoma [14, 15] 
10. Liquid biopsy diagnosis of gliomas using cerebrospi-
nal fluid (CSF) [16, 17] 
 
Of note, the ranking in this list is not based on im-
portance of the findings, but rather on an attempt to 
create a flow in this review (from information that may 
quite readily be implemented in daily diagnostic practice 
via more hard-core neurobiology/neuroscience findings 
to some future perspectives). Also, there is a bias in the 
selection of the topics in this list towards diffuse gliomas 
and embryonal tumors/medulloblastomas. Obviously, 
other colleagues might have presented a quite different 
list of ‘top 10 discoveries’, also because many more very 
good and interesting papers with implications for neuro-
oncological pathology were published in 2019. For ex-
ample, the study of Paramasivam et al [18], providing 
novel information on mutational patterns and regulatory 
networks of subgroups of meningiomas would be a good 
alternative for a topic. Having said that, it is hoped that 
this review not only provides easily digestible infor-
mation on the top 10 discoveries in neuro-oncological 
pathology as selected by this author, but will also be 
used as a stepping stone to appreciate the much more 
detailed information in the original papers that were 
used as building blocks for this review. 
Topic 1. Lack of H3K27me3 staining is 
a promising surrogate marker for oli-
godendrogliomas [1] 
Unequivocal histological recognition of (anaplastic) 
oligodrogliomas, IDH-mutant & 1p/19q-codeleted (‘ca-
nonical oligodendrogliomas’) has been hindered by the 
lack of specific immunohistochemical markers for these 
tumors [19]. In a study analyzing an epigenetically well-
defined cohort of diffuse gliomas in adults (IDH-mutant 
& 1p/19q-codeleted oligodendrogliomas, n = 26; IDH-
mutant astrocytic tumors, n = 34; IDH-wildtype glioblas-
tomas, n = 101), Filipski et al report that 25 out of the 26 
oligodendrogliomas showed lack of nuclear H3K27me3 
staining, in the remaining case H3K27me3 staining was 
interpreted as non-conclusive [1]. Interestingly, in an 
otherwise ‘nucleonegative’ oligodendroglioma of a fe-
male patient only dot-like nuclear staining was seen. 
This phenomenon has previously been described to 
represent the inactivated X chromosome, with 
H3K27me3 functioning as a transcriptional silencing 
mechanism via chromatin remodeling [20] (Fig. 1). The 
vast majority of IDH-mutant and IDH-wildtype astrocytic 
tumors showed clear nuclear H3K27me3 staining. Based 
on these findings in combination with the results of 
immunohistochemistry for ATRX, IDH1R132H and 
H3K27M, Filipski et al report that in their cohort of 
H3K27-wildtype diffuse gliomas the tumors showing lack 
of nuclear H3K27me3 staining, retention or non-
conclusive nuclear ATRX staining, and IDH1R132H muta-
tion are oligodendroglioma, IDH-mutant & 1p/19q 
codeleted with a predicted probability of 0.9678. Ideally, 
in case of H3K27me3- and H3K27M-nucleonegative 
diffuse gliomas that in addition show retained or non-
conclusive ATRX staining but no IDH1R132H-mutant 
protein staining, sequencing analysis is performed to 
demonstrate presence/absence of an IDH1 or IDH2 mu-
tation. Obviously, the results of immunohistochemistry 
should be interpreted with caution in especially biopsies 
that are small and/or only show low tumor cell percent-
age. The use of an antibody panel including H3K27me3, 
H3K27M mutant protein, ATRX, and IDH1R132H may 
thus greatly facilitate recognition (anaplastic) oligoden-
drogliomas, IDH-mutant & 1p/19q-codeleted, especially 
so in a situation where molecular testing is not readily 
available/possible. The pathobiology underlying the 
global lack of H3K27me3 in tumor cell nuclei and 1p/19q 
codeletion needs further elucidation. 
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Fig. 1. Lack of nuclear H3K27me3 immunohistochemical staining; a surrogate marker for oligodendroglioma, IDH-mutant and 1p/19q-
codeleted. 
In the past, the diagnosis oligodendroglioma was mainly based on histology in Hematoxylin and Eosin (H&E) stained sections, the ‘fried 
egg’ phenotype of the tumor cells being an important clue for this diagnosis (a); nowadays, demonstration of IDH-mutant status and 
(complete) 1p/19q codeletion is required for the diagnosis of ‘canonical’ oligodendroglioma (b; result of methylome analysis showing 
(with almost perfect calibrated score of 0.99) suggested diagnosis of oligodendroglioma, IDH-mutant and 1p/19q-codeleted, as well as 
copy number profile based on methylome analysis with loss of chromosome arms 1p and 19q, and hypermethylated status of MGMT 
promoter); Filipski et al report that immunohistochemistry can be used to recognize ‘canonical’ oligodendrogliomas as well, the combi-
nation of lack of nuclear H3K27me3 staining, retention or non-conclusive nuclear ATRX staining, and positive staining for IDH1R132H 
mutant protein in H3K27-wildtype diffuse gliomas being highly suggestive for this diagnosis (c; while the nuclei of non-neoplastic cells in 
the microvessel wall show strong H3K27me3 staining (arrowheads), the tumor cell nuclei (arrows) are largely negative; in this female 
patient, the remaining positive dots in the tumor cell nuclei represent the inactivated X chromosome [20]). 
 
 
Of note, while in diffuse gliomas in adults lack of 
H3K27me3 staining may thus indicate canonical oli-
godendroglioma with a relatively favorable prognosis, in 
several other tumors of the (central) nervous system 
(e.g. posterior fossa ependymomas, malignant peripher-
al nerve sheath tumors, meningiomas) such a lack of 
nuclear staining is associated with worse prognosis [21-
23]. 
Topic 2. Improved molecular diagnosis 
of rare CNS tumor types [2, 3] 
Only recently, genome-wide DNA methylation 
analysis has been introduced as a very helpful tool for 
improved diagnosis of CNS tumor types and subtypes 
[24-29]. In 2019, two papers were published by the ‘Hei-
delberg team’ + coauthors from other centers/countries 
demonstrating the power of methylome analysis. Sievers 
et al [2] report the results of in-depth analysis of 30 
tumors initially identified through methylome analysis as 
a separate group in a Heidelberg cohort of > 25,000 
tumors. Most tumors in this group were histologically 
diagnosed as rosette-forming glioneuronal tumor 
(RGNT), and all revealed FGFR1 hotspot mutations, with 
in about two-thirds of the cases co-occurrence of a 
PIK3CA mutation and in one third of the tumors an addi-
tional loss-of-function mutation in NF1. In contrast to 
most low-grade gliomas, RGNTs displayed co-occurrence 
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of two or even all three of these mutations. These highly 
recurrent combined genetic alterations affecting both 
MAPK and PI3K signaling pathways may offer potential 
therapeutic targets for RGNTs [2]. In a study of Hou et al 
[3], 17 of the 28 tumors initially histologically diagnosed 
as papillary glioneuronal tumor (PGNT) showed methyla-
tion profiles typical for other tumor entities (mostly 
dysembryoplastic neuroepithelial tumor and pilocytic 
astrocytoma). The remaining 11 cases exhibited a unique 
profile and were considered as a distinct PGNT methyla-
tion class. Three additional tumors in the Heidelberg 
cohort clustered with this methylation class as well but 
were originally not diagnosed as PGNT. In all 12 cases of 
this methylation class of which material was available for 
further analysis, fusions involving PRKCA were identified 
(SLC44A1–PRKCA, n = 11; NOTCH1-PRKCA, n = 1), where-
as such fusions were not found in the tumors belonging 
to other methylation classes. Both the study of Sievers 
et al and of Hou et al thus provide information on mo-
lecular characteristics that can be used for improved 
recognition of such rare CNS tumor types and again 
illustrate the power of methylome analysis in this con-
text. 
Topic 3. Refined molecular classifica-
tion of non-WNT/non-SHH medullo-
blastomas [4] 
The 2016 WHO Classification of CNS tumors recog-
nizes four molecular variants of medulloblastoma: WNT-
activated, SHH-activated and TP53-mutant, SHH-
activated and TP53-wildtype, and non-WNT/non-SHH. 
The non-WNT/non-SHH subgroup, accounting for about 
65% of all medulloblastomas, encompasses the Group 3 
and Group 4 molecular variants of medulloblastoma. 
However, these groups have heterogeneous clinical 
characteristics and survival outcomes, and their biology 
remained less clear. Studies published in 2017 suggested 
the existence of 4, 6 or 8 subgroups within the overarch-
ing non-WNT/non-SHH group [30-32]. In an attempt to 
provide clarity and a basis for further biological studies, 
Sharma et al analyzed the number and nature of sub-
types that could be identified in a cohort of 1501 ge-
nomically characterized non-WNT/non-SHH medullo-
blastomas [4]. In this study, rather than advocating one 
single analytical approach or method, multiple class-
definition approaches were used and equal weight was 
given to each analytical technique. In a lower complexity 
analysis Group 3 and Group 4 were identified again, but 
more complex analysis strongly supported the existence 
of eight robust Group 3/Group 4 subtypes (I-VIII). These 
subtypes could generally be recognized based on their 
DNA-methylation profiles and showed differences in 
enrichment for specific driver gene alterations, cytoge-
netic events, and ages of incidence with mostly unimod-
al age distribution. Cytogenetic signatures, chromosomal 
copy-number aberrations and information on one gene 
or a set of genes in isolation were found to be insuffi-
cient for recognition of subtypes I-VIII. The relevance of 
these subtypes is supported by differences in survival, 
with e.g. subtype IV being associated with low-risk clini-
cal behavior, and with relatively frequent late relapses in 
patients with a subtype VIII medulloblastoma. These 
findings can be expected to improve risk stratification, 
therapy and thereby the outcome for patients with non-
WNT/non-SHH medulloblastomas. Of note, although the 
bimodal age distribution that was found for subtypes V 
and VII may indicate that some further refinement of the 
classification is still possible, the authors report that they 
did not find strong evidence for more than eight molecu-
lar subgroups in the non-WNT/non-SHH category. Sub-
typing of non-WNT/non-SHH medulloblastomas into 
subtype I-VIII is now available for the community by 
performing methylome analysis as described by Capper 
et al [24, 25] and using an extension of the Heidelberg 
brain tumor classifier (https://www.molecularneuro
pathology.org/mnp/classifier/7). 
Topic 4. Histogenesis of posterior fos-
sa tumors in children [5-7] 
For quite some time it is clear that different sub-
types of medulloblastomas have different developmen-
tal origin [33]. In fact, cerebellar tumors may be the 
result of a disorder of early cerebellar development. In 
an attempt to further elucidate cerebellar development 
at the single cell level, Vladiou et al performed large-
scale single-cell RNA sequencing (scRNA-seq) of more 
than 60,000 cells from the developing mouse cerebellum 
[5]. These analyses allowed them to reconstruct the 
cellular hierarchy in development at various points in 
time, with many of the normal mouse cerebellar cell 
populations only being present for a restricted time 
period during the fetal or very early postnatal period. 
Subsequently, this transcriptome information was com-
pared to that of pediatric cerebellar tumors: medullo-
blastomas, posterior fossa (PF) ependymomas, and pilo-
cytic astrocytoma. The authors find that (different mo-
lecular subgroups of) these tumors indeed mirror the 
transcription of cells from distinct, temporally restricted 
cerebellar lineages: SHH medulloblastomas, Group 3 and 
Group 4 medulloblastomas were found to transcription-
ally resemble respectively the granule cell hierarchy, 
Nestin+ stem cells, and unipolar brush cells, while PF 
type A/PF type B (PFA/PFB) ependymomas and cerebel-
lar pilocytic astrocytomas resembled prenatal gliogenic 
progenitor cells. These findings indicate that each of 
these cerebellar tumor types arises from a particular cell 
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type. However, across the medulloblastoma subgroups 
(SHH, Group 3, Group 4), as well as PFA ependymoma 
and pilocytic astrocytomas, the scRNAseq data also 
demonstrated high levels of single-cell heterogeneity, 
with evidence of multiple lineages of differentiation and 
tumor cells matching different time points in the differ-
entiation hierarchy [5]. In another study, Hovestadt et al 
performed single-cell transcriptomics to investigate 
intra- and intertumoral heterogeneity in 25 medulloblas-
tomas spanning all molecular subgroups. They find that 
WNT, SHH and Group 3 tumors comprise subgroup-
specific undifferentiated and differentiated neuronal-like 
populations of malignant cells, whereas Group 4 tumors 
consist of differentiated neuronal-like neoplastic cells. 
The tumor cells in SHH medulloblastomas closely resem-
bled granule neurons of varying differentiation states 
that correlated with patient age. Using cross-species 
transcriptomic analysis, it appeared that distinct glu-
tamatergic populations are the putative cells-of-origin 
for SHH and Group 4 medulloblastomas. Furthermore, 
the tumor cells of Group 3 and Group 4 medulloblasto-
mas exhibited characteristics ranging from primitive 
progenitor-like to more mature neuronal-like cells, with 
the relative proportions of these cells distinguishing 
these subgroups [6]. In a third study, based on single-cell 
transcriptome analysis of >65,000 cells of the embryonal 
pons and forebrain, Jessa et al derived signatures for 191 
distinct cell populations of these regions [7]. Bulk tran-
scriptome analysis of WNT-activated medulloblastomas 
revealed a match with the mossy fiber neuronal lineage 
of the rhombic lip. Embryonal tumors with multilayered 
rosettes (ETMRs) appeared to be derived from a neu-
ronal lineage as well, but especially the TYR and MYC 
subgroups of atypical teratoid/rhabdoid tumor (AT/RT) 
seemed to originate from non-neuroectodermal cells. All 
in all, these studies provide strong evidence that pediat-
ric CNS tumors are the result of a disorder of early de-
velopment, although the possibility that they arise from 
more mature cells undergoing de-differentiation at later 
time points or from trans-differentiation of other cell 
lineages cannot yet be completely ruled out. 
Topic 5. Longitudinal molecular analy-
sis of diffuse gliomas [8] 
Genomic characterization efforts such as The Can-
cer Genome Atlas (TCGA) have greatly increased our 
understanding of glioma biology [34-37]. Based on these 
findings three major, clinically relevant subgroups of 
diffuse gliomas in adults were introduced in the WHO 
2016 classification of CNS tumors: (1) IDH-mutant and 
chromosome 1p/19q codeleted (IDH-mutant-codel); (2) 
IDH-mutant without codeletion of chromosome 1p/19q 
(IDH-mutant-noncodel); and (3) IDH-wildtype. So far, 
however, such studies were generally limited to analysis 
of tumor tissue as obtained by first operation, and how 
the genetic landscape of these gliomas evolves over time 
and in response to therapy remained largely unknown. 
In December 2019, the Glioma Longitudinal AnalySiS 
(GLASS) Consortium published the results of analysis of 
222 diffuse glioma patients (25 IDH-mutant-codel, 63 
IDH-mutant-noncodel, and 134 IDH-wildtype) with high-
quality data on mutations and chromosomal copy num-
bers in samples of at least two time points [8]. The study 
revealed that the driver genes detected in the initial 
sample were retained in the recurrent tumor, and there 
was little evidence of recurrence-specific gene altera-
tions. Also, current standard of care therapies (chemo-
therapy, irradiation) generally did not seem to coerce 
the tumors down predictable paths. IDH-mutant-
noncodels were found to be most sensitive to develop-
ing a hypermutator phenotype after therapy with alkyl-
ating agents, a phenomenon that has been reported 
before [38, 39]. Importantly, no differences were found 
in overall survival between hypermutators and non-
hypermutators independent of age, subtype and MGMT 
promoter methylation status. In line with a recent study 
demonstrating that homozygous CDKN2A loss is a mark-
er for high-grade malignancy in IDH-mutant-noncodels 
[40], in the GLASS study recurrent IDH-mutant-
noncodels were enriched for homozygous CDKN2A dele-
tions and this was associated with shorter survival com-
pared to patients without these alterations. No differ-
ences in the levels of immunoediting were found be-
tween initial and recurrent gliomas. The GLASS study 
thus indicates that the strongest selective pressure in 
these three major subgroups of diffuse gliomas occurs 
during early glioma development and that current ther-
apies shape this evolution in a largely stochastic manner. 
Hopefully, such information on how diffuse gliomas 
evolve over time and in response to therapy will help to 
design more efficacious therapeutic strategies for these 
tumors. 
Topic 6. NOTCH1-SOX2 signaling con-
trols glioma cell invasion in white 
matter tracts [9] 
One of the main reasons that patients with diffuse 
gliomas so far cannot be cured is the diffuse infiltrative 
growth of the tumor cells along white matter tracts. One 
would hope that unraveling the mechanisms underlying 
this phenomenon may help to identify novel therapeutic 
targets. In an analysis of human glioma tissue samples, 
Wang et al found that at the invasive front, CD133+ ‘gli-
oma stem cells’ (GSCs) were preferentially located along 
white matter tracts [41]. Also, these tracts showed sig-
nificant swelling and seemed to have discontinuous 
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myelin, indicating that some GSCs in the glioma-brain 
interface are preferentially located adjacent to unmye-
linated white matter tracts. Based on their findings the 
authors postulate that glioma invasion along these tracts 
occurs along axons inside myelin sheaths rather than 
along the outer surface of such sheaths, and that glioma-
associated edema may play a role in local destruction of 
white matter fibers and thereby pave the way for direct 
interaction of glioma cells and axons. Additionally, based 
on their findings in preclinical experiments that nearly all 
CD133+ GSCs were also Notch1+ and that nerve fibers at 
the invasive frontier all expressed Jagged1, Wang et al 
postulate that the interaction between Jagged1 and 
Notch1 may be an important determinant for the distri-
bution of GSCs. Indeed, axonally expressed Jagged1 was 
found to activate the Notch signaling pathway in GSCs 
and to subsequently promote the transcription of SOX2 
via SOX9. Conversely, SOX2 upregulation decreased the 
methylation of the NOTCH1 promoter to reinforce the 
high expression of NOTCH1 in GSCs and facilitate their 
white matter-tract tropism, while inhibition of Notch 
signaling was found to attenuate this tropism. The find-
ings of Wang et al indicate that the NOTCH1-SOX2 posi-
tive-feedback loop is an important determinant of GSC 
invasion along white matter tracts, and that molecules in 
this loop may be exploited as therapeutic targets. How-
ever, the authors acknowledge that the mechanisms 
underlying glioma cell invasion along white matter tracts 
are probably more complex, and may also involve mech-
anisms as discussed in the next topic (Topic 7). 
Topic 7. ‘Synaptic cooption’ in glial 
and metastatic CNS tumors [10-12] 
After reporting earlier that neuroligin-3 secreted 
by active neurons promotes glioma growth [42, 43], in a 
recent study published in Nature, Venkatesh et al found 
that electrochemical communication exists between 
neurons and glioma cells through bona fide AMPA (α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) 
receptor-dependent synapses between these cells [10]. 
Also, neuronal activity was found to evoke non-synaptic 
activity-dependent potassium currents that were ampli-
fied by gap junction-mediated tumor interconnections 
and resulting in an electrically coupled network. Depo-
larization of glioma membranes was found to promote 
proliferation, whereas blocking electrochemical signaling 
inhibited the growth of glioma xenografts in mice. In-
traoperative electrocorticography in glioma patients 
revealed increased cortical excitability in the glioma-
infiltrated brain areas. Based on these findings the au-
thors suggest that glioma growth is promoted by synap-
tic and electrical integration into neural circuits, with 
glioma-induced increase in neuronal excitability and 
activity-regulated glioma growth as elements of a posi-
tive feedback loop. In the same issue of Nature, Venka-
ratamani et al also report that functional synapses be-
tween neurons and glioma cells exist [11]. Previously, 
these authors already demonstrated that many tumor 
cells in astrocytic tumors including glioblastomas extend 
ultra-long membrane protrusions (microtubes) that are 
used for brain invasion and proliferation, and that inter-
connect over long distances [44] (Fig. 2). 
 
Fig. 2. Human glioma cells forming a mycelium-like network 
in mouse brain. 
Based on findings in especially two-dimensional histological 
slides, tumor cells in the periphery of diffuse gliomas have 
been considered as ‘guerilla warriors’ that move as single cells 
into the preexistent CNS tissue [41]. More recent findings, 
however, show that such cells in diffuse astrocytic tumors form 
a network of microtubes. This figure shows such network 
formation by human glioblastoma cells 28 days after implanta-
tion into a mouse brain (yellow: glioblastoma cells labeled by 
human-specific anti-vimentin antibody; magenta: mouse astro-
cytes labeled by anti-GFAP antibody; blue: cell nuclei labeled 
by DAPI; figure kindly provided by Pavel Gritsenko and Peter 
Friedl and based on work recently published [61]). In addition 
to such a mycelium-like network formation, studies discussed 
under Topic 7 now report that direct, biologically relevant 
synaptic communication exists between neurons and tumor 
cells as well. 
 
In their recent study, Venkaratamani et al show the 
presence of ‘neurogliomal synapses’ in human glioma 
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samples and in different disease models. Such synapses 
were found to be located on tumor microtubes and 
produce postsynaptic currents that are mediated by 
glutamate receptors of the AMPA subtype. In their ex-
periments, neuronal activity led to synchronized calcium 
transients in tumor-microtube-connected glioma net-
works. Furthermore, perturbation of AMPA receptors 
and use of an AMPA receptor antagonist reduced calci-
um-related invasiveness of tumor cells and of glioma 
growth. Intriguingly, in a third study published in that 
same issue of Nature, Zeng et al demonstrate the exist-
ence of ‘pseudo-tripartite synapses’ between breast 
cancer cells and glutamatergic neurons and show that 
such cancer cells in the brain can co-opt a neuronal sig-
naling pathway involving activation by glutamate ligands 
of N-methyl-D-aspartate receptors (NMDARs) [12]. 
These three studies thus suggest very peculiar brain 
tumor-microenvironment interactions in the form of 
direct, biologically relevant synaptic communication 
between neurons and tumor cells with potential thera-
peutic implications. 
Topic 8. Cancer stem cells in glioblas-
tomas; do they exist? [13] 
It is been proposed that in glioblastomas cancer 
stem cells (CSCs) or stem-like cells reside at the top of a 
hierarchical organization, are able to (re)create intra-
tumoral heterogeneity by generating more differentiat-
ed offspring, and are relatively resistant to therapy and 
thus contribute significantly to tumor recurrence [45]. 
Expression of particular cell membrane antigens (CD133, 
CD15/SSEA, CD44, and/or A2B5) has often been used for 
identification of the CSC subset in glioblastomas. How-
ever, it is increasingly clear that no single marker allows 
for unequivocal identification of a CSC population in 
glioblastomas. Moreover, there is still controversy if a 
bona fide CSC population exists at all (and if so, if it con-
cerns a quiescent or proliferative subpopulation). In this 
context, Dirkse et al addressed the question whether 
glioblastoma cells expressing CSC-associated cell mem-
brane markers are indeed a defined entity at the apex of 
a hierarchical organization. They found that, like in pa-
tient biopsies, CSC markers were heterogeneously ex-
pressed in patient-derived glioblastoma xenografts and 
stem-like cell cultures. More precisely, all FACS-sorted 
subpopulations of tumor cells of glioblastomas were 
able to self-renew over multiple passages without signif-
icant differences between each other. This suggests that 
phenotypically heterogeneous glioblastoma cells can 
adapt to a variety of environmental changes and acquire 
similar stem cell properties in vitro. Dirkse et al also 
found that accelerated reconstitution of heterogeneity 
provided a growth advantage in vivo, suggesting that 
tumorigenic potential is linked to intrinsic plasticity ra-
ther than CSC multipotency. The study of Dirkse et al 
thus provides strong evidence that CSCs do not consti-
tute a defined cellular entity, but rather a cellular state 
adapting to microenvironmental cues. The capacity of 
any given tumor cell to reconstitute heterogeneity in 
glioblastomas cautions against therapies targeting only a 
small subpopulation of tumor cells with stem cell(-like) 
characteristics. Meanwhile, inherent cancer cell plastici-
ty emerges as a novel relevant target for treatment [13]. 
Topic 9. Personalized (neo)antigen 
vaccination therapy for glioblastoma 
[14, 15] 
In patients with e.g. melanomas, high tumor muta-
tional load (TML) is associated with increased frequency 
of neoantigens and improved response to checkpoint 
inhibition. Administration of personalized neoantigen 
vaccines has been shown to successfully recruit T cells to 
the tumor and can lead to tumor regression. Unfortu-
nately, also after the introduction of immunotherapies, 
so far the very poor survival rates for patients with glio-
blastoma have not improved much. Of note, glioblasto-
mas often have a relatively low mutational burden and 
are considered as immunologically ‘cold’. Recent studies 
suggest that for patients with glioblastoma, a personal-
ized molecular approach is needed to improve the bene-
fit of treatment with programmed cell death protein 1 
(PD-1) inhibitors nivolumab or pembrolizumab, and that 
the neoadjuvant administration of PD-1 blockade may 
represent a more efficacious approach for these tumors 
[46, 47]. Two recent studies published in Nature ex-
plored the feasibility of vaccination therapy using tumor 
(neo)antigens for patients with glioblastoma. Keskin et al 
performed a phase I/Ib multi-epitope, personalized neo-
antigen vaccination study [14]. Patients who did not 
receive dexamethasone generated circulating polyfunc-
tional neoantigen-specific CD4+ and CD8+ T cell respons-
es that were enriched in a memory phenotype. After 
vaccination, neoantigen-specific T cells were found to 
migrate from peripheral blood into the glioblastoma, 
suggesting that they may favorably alter the immune 
milieu of the tumor [14]. Hilf et al studied vaccination 
using both unmutated tumor antigens and neoepitopes 
for more effective immunotherapy of glioblastomas, 
including those with a low mutational load [15]. Highly 
individualized vaccinations with both types of tumor 
antigens were integrated into standard care for patients 
with newly diagnosed glioblastoma. Fifteen patients 
were first treated with a vaccine with a previously con-
structed library of non-mutated antigens that are over-
represented in glioblastomas (APVAC1), followed by a 
second vaccine (APVAC2) targeted against mutated 
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neoantigens or non-mutated antigens that were not 
present in APVAC1. The vaccines were personalized by 
analysis of mutations and of the transcriptomes and 
immunopeptidomes of the individual tumors. Both vac-
cines showed favorable safety and elicited T cell re-
sponses against the proteins in the vaccine, with 
APVAC1 inducing a sustained CD8+ T cell response, and 
APVAC2 both CD4+ and CD8+ T cell responses [15]. 
Topic 10. Liquid biopsy diagnosis of 
gliomas using CSF [16, 17] 
Cancer cells release nucleic acids, vesicles, pro-
teins, and other components into the blood stream and 
other body fluids. Already for quite some time, circulat-
ing tumor DNA (ctDNA) in blood is considered as an 
easily accessible source of potentially very useful diag-
nostic, prognostic and/or predictive information that can 
be used to improve the management of cancer patients 
[48]. So far, however, liquid biopsy diagnosis for detec-
tion and monitoring of patients with gliomas has not yet 
entered the clinic. Part of the problem may be that, 
compared to other cancers, gliomas release relatively 
limited amounts of ctDNA into the bloodstream [49]. 
Sequencing of ctDNA from the cerebrospinal fluid (CSF) 
may provide an alternative way to diagnose glial and 
other CNS tumors. Indeed, in 42 out of 85 adult patients 
with diffuse glioma (49.4%), Miller et al detected ctDNA 
in CSF that was obtained by lumbar puncture [16]. Pres-
ence of ctDNA was associated with disease burden and 
adverse outcome. The glioma genomes detected in CSF 
closely resembled those in matched tumor samples. 
Alterations occurring early in gliomagenesis (IDH1/IDH2 
mutation, 1p/19q codeletion) were shared in all 
matched ctDNA-positive CSF-tumor pairs, whereas 
growth factor receptor signaling pathways showed con-
siderable evolution. Most patients with ctDNA-positive 
CSF did not have detectable malignant cells in the CSF, 
and no significant association was found between 
ctDNA-positive CSF and glioma grade, disease duration 
or prior therapy. Of note, in this study of Miller et al the 
CSF samples were derived from patients relatively late in 
their disease course (median disease duration before 
CSF collection for patients with IDH-wildtype glioblasto-
mas about a year, and for patients with IDH-mutant 
lower grade gliomas over 5 years), and all patients al-
ready had treatment for their glial tumor. In contrast, 
Pan et al explored the potential of ctDNA analysis in CSF 
obtained prior to surgical manipulation in a cohort of 57 
patients with brainstem glioma [17]. Over 90% of these 
CSF samples were obtained intraoperatively. Pan et al 
report that alterations were identified in the CSF ctDNA 
in 36/37 cases (97.3%) in which the primary tumors 
harbored at least one mutation, while in 31/37 of cases 
(83%) all primary tumor alterations were detected in the 
CSF. In these patients, mutation detection using plasma 
ctDNA was found to be much less sensitive than se-
quencing the CSF ctDNA. These studies thus suggest that 
indeed CSF may be a much more promising biosource 
for liquid biopsy diagnostics of gliomas than blood. 
Combination of such an approach with analyses going 
beyond DNA sequence information (e.g. analysis of epi-
genetic and immune signatures in cell free DNA) may 
further boost the exploitation of liquid biopsy diagnos-
tics in patients with (glial) CNS tumors [49]. 
Discussion 
The papers discussed in this review as top 10 dis-
coveries illustrate the substantial and sometimes even 
amazing progress that has been made in increasing our 
understanding of particular topics in neuro-oncological 
pathology. Hopefully, this review not only provides easi-
ly digestible information on the topics selected by the 
author, but also works as a stepping stone to read and 
appreciate the original papers that were used as building 
blocks for the present manuscript. Obviously, most of 
the findings presented here immediately elicit next 
questions. For example, are the findings presented by 
Filipski et al already ‘mature’ enough to be used as sur-
rogate markers for the diagnosis of (anaplastic) oli-
godendroglioma, IDH-mutant and 1p/19q-codeleted in 
clinical practice? And while Wang et al report that the 
NOTCH1-SOX2 positive-feedback loop is an important 
(and possibly targetable) determinant of invasion of 
glioma cells along white matter tracts, the authors 
acknowledge that other mechanisms as discussed in 
Topic 7 may be involved as well. But then again, is syn-
apse formation between neuronal and glioma cell pro-
cesses especially relevant for the invasive front? Or also 
for proliferation of tumor cells in the highly cellular cen-
ter of glioblastomas where neurites can be expected to 
be (much) more scarce? What about the presence of 
‘pseudo-tripartite synapses’ in the ‘bulky’ areas of meta-
static breast cancer in the CNS? And (see Topic 8): Do 
bona fide glioma stem cells exist? 
Nowadays, a rapidly increasing number of diagnos-
tic and prognostic molecular markers can be used for an 
improved, ‘histo-molecular’ diagnosis of CNS tumors 
[50]. Multiple assays have been developed for this pur-
pose, ranging from single gene tests to high-throughput, 
integrated techniques enabling detection of multiple 
genetic aberrations in a single workflow [51]. Immuno-
histochemistry is a helpful, relatively inexpensive alter-
native for further molecular characterization of particu-
lar CNS tumors. Within a few years after its introduction, 
genome-wide methylation profiling has already had a 
revolutionary impact on CNS tumor classification [24, 25, 
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52]. The papers discussed in Topic 2 (‘Improved molecu-
lar diagnosis of rare CNS tumor types’) provide examples 
of the strength of this platform. However, such 
methylome analysis is relatively expensive. Obviously, a 
test providing clinically very valuable information at low 
costs will much more easily be accepted as a routine 
diagnostic tool compared to an expensive test with lim-
ited clinical benefits. Unfortunately, a clear framework 
for assessment of cost-effectiveness of molecular testing 
of CNS (and other) tumors is lacking [53]. It is important 
to realize though that molecular diagnostics of (CNS) 
tumors is relatively inexpensive compared to e.g. neuro-
imaging and chemotherapy, and that a diagnosis that is 
‘on target’ will not only have substantial clinical benefit 
for the patients but may also help to avoid unnecessary 
health care costs [52, 54]. 
Meanwhile, since the publication of the WHO Clas-
sification of CNS Tumours in 2016, the consortium to 
Improve Molecular and Practical Approaches into CNS 
tumor Taxonomy (cIMPACT-NOW) has already published 
several updates with suggestions on how exactly particu-
lar molecular markers can be used for improved diagno-
sis in clinical practice (see for summary of round 1 up-
dates [55]). The findings described in Topic 3 (‘Refined 
molecular classification of non-WNT/non-SHH medullo-
blastomas‘) and Topic 4 (‘Histogenesis of posterior fossa 
tumors in children’) may soon be incorporated into a 
more refined next WHO classification of these tumors 
(5th edition expected to be published within a year from 
now!). When shaping a WHO classification, one may 
indeed follow such a more progressive approach (i.e. 
introduce the latest tools and findings and include e.g. 
the most refined subclassification of non-WNT/non-SHH 
medulloblastomas), or be somewhat more conservative 
in an attempt to better preserve long-term correlations, 
to avoid major disruption of patient management, 
and/or because of limited availability of (often expen-
sive) diagnostic tools. Obviously, finding the right bal-




Fig. 3. ‘Strings attached’ to designing a next WHO classification of (CNS) tumors. 
Finding the right balance between a conservative and progressive attitude with regard to incorporating the latest findings into a next 
WHO tumor classification is key but can be challenging, not only because there are many strings attached, but also because of different 
aspects of the underlying dynamics. Figure based on input of Dr. David N. Louis. 
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Next to diagnostic and prognostic markers, clinical 
neuropathologists are increasingly asked to perform 
testing for predictive biomarkers, e.g. for assessment of 
the likelihood of response of gliomas to particular im-
munotherapeutic approaches. Only a limited number of 
newly diagnosed gliomas is reported to have an (occa-
sionally inherited) mismatch repair (MMR) defect and/or 
a ‘hypermutator’ phenotype. Recurrent gliomas more 
often show such a phenotype, especially so after alkylat-
ing chemotherapy [8]. Assuming that the hypermutator 
status leads to an increase in expression of neoantigens, 
these gliomas/glioblastomas with a hypermutator phe-
notype could be good candidates for immune check-
point blockade. Unequivocal scoring of immunohisto-
chemical staining for PD1/PD-L1 (surface proteins on 
tumor-infiltrating lymphocytes and tumor cells, respec-
tively, and involved in suppression of the immune sys-
tem) can be challenging. Alternatively, MMR deficiency, 
microsatellite instability (MSI), DNA polymerase epsilon 
(POLE) mutations, and high tumor mutational load (TML) 
are being used in this context, but assessment of these 
biomarkers can be challenging as well. For example, 
MMR gene (MLH1, MSH2, MSH6, and/or PMS2) muta-
tions often, but not always lead to lack of immunostain-
ing of tumor cell nuclei for the corresponding protein(s). 
Also, the techniques and thresholds to be used for opti-
mal assessment of high TML are not yet settled. While 
for non-small cell lung carcinoma ≥10 mutations per Mb 
is considered as high TML, it is unclear if this threshold 
should be used for gliomas as well [56, 57]. Of course, 
identification and optimization of biomarkers for re-
sponse to immunotherapy only makes sense if at least 
some patients can be expected to significantly benefit 
from that particular therapy. Furthermore, the studies 
reported under Topic 9 (‘Personalized (neo)antigen vac-
cination therapy for glioblastoma’) indicate that bi-
omarker discovery in this context is a moving target. 
In conclusion, ‘the times they are a-changin’ 
and one can expect that there is much more 
change to come. Liquid biopsy-based diagnoses 
may emerge soon as a clinically helpful source of 
information. Furthermore, a very recently pub-
lished study showed that the use of artificial intelli-
gence outperformed radiologists in the mammo-
gram-based prediction of breast cancer [58]. Simi-
larly, deep learning/machine learning approaches 
may increasingly be used for automated, histology-
based brain tumor classification and/or for predict-
ing molecular markers based on MRI or other neu-
ro-imaging modalities [59, 60]. Such developments 
could have significant impact on the ‘core business’ 
of the (neuro)pathologist. However, to quote the 
Editor-in-Chief of Free Neuropathology: ‘As long as 
neuropathology continues to be creative and inno-
vative at the forefront of classifying and diagnosing 
neurological disorders and revealing their molecu-
lar pathogenesis …, its future will be bright’ [52]. 
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